<DOC>
	<DOCNO>NCT03047863</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic efficacy topical EGF cream dermatologic adverse event related EGFR inhibitor .</brief_summary>
	<brief_title>Therapeutic Effect EGF Cream Cutaneous Adverse Event EGFR Inhibitors</brief_title>
	<detailed_description>Epidermal growth factor receptor ( EGFR ) involve cell proliferation overexpressed abnormally activate malignant tumor originate colon , breast , ovary , pancreas , lung . EGFR tyrosine kinase inhibitor ( TKI ) , gefitinib , erlotinib , afatinib treatment cancer associate EGFR gene mutation . In addition , monoclonal antibody EGFR , cetuximab panitumumab , use chemotherapy rectal cancer without ra gene mutation advance head neck cancer . The incidence cutaneous toxicity EGFR inhibitor report 75-80 % . Clinical feature include acneform folliculitis , xerosis , paronychia , itch . Of , 10 % patient Grade 3 great detrimental effect quality life adherence treatment , result impaired therapeutic result . There many attempt prevent treat skin toxicity . However , scientifically proven treatment . There grow interest role EGF emulsifier treatment skin adverse effect EGFR inhibitor , result study improve acne significantly compare placebo . The purpose study evaluate therapeutic efficacy EGF cream treatment skin adverse effect patient malignant tumor treat EGFR inhibitor ( TKI monoclonal antibody ) .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>Patients receive EGFR inhibitor ( gefitinib , erlotinib , afatinib , cetuximab , etc . ) malignant tumor Patients EGFR inhibitorassociated skin reaction : National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCICTCAE V4.03 ) Grade 2 , 3 Patients Patients understand follow protocol Patients spontaneously agree study NCICTCAE grade 4 patient require systemic drug therapy Those history antibiotic treatment , local systemic steroid therapy within 4 week reason EGFR inhibitor Patients exist acne history Patients already receive antiEGFR therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epidermal Growth Factor</keyword>
</DOC>